Literature DB >> 28240808

Prognostic effect of transarterial chemoembolization-induced complete pathological response in patients undergoing liver resection and transplantation for hepatocellular carcinoma.

Woo-Hyoung Kang1, Shin Hwang1, Gi-Won Song1, Young-Joo Lee1, Ki-Hun Kim1, Chul-Soo Ahn1, Deok-Bog Moon1, Dong-Hwan Jung1, Gil-Chun Park1, Sung-Gyu Lee1.   

Abstract

Transarterial chemoembolization (TACE)-induced complete pathological response (CPR) is known to improve postresection outcomes of hepatocellular carcinoma (HCC). We aimed to assess the prognostic effects of CPR after preoperative TACE for HCC in patients who underwent hepatic resection (HR) or liver transplantation (LT). The clinical outcomes of patients showing CPR after HR (n = 110) or LT (n = 233) were analyzed. The control groups comprised patients with minimal recurrence risk as naïve single HCC ≤ 2 cm for HR (n = 476), and 1 or 2 HCCs ≤ 2 cm for LT (n = 184). Among HR study patients, 1-, 3-, and 5-year tumor recurrence rates were 18.5%, 50.6%, and 58.7% respectively, which were higher than those of controls (P < 0.001). The 1-, 3-, and 5-year patient survival rates were 97.8%, 82.0%, and 69.1%, respectively, which were lower than those of controls (P < 0.001). Among LT study patients, 1-, 3-, and 5-year tumor recurrence rates were 4.1%, 7.9%, and 7.9%, respectively, which were higher than those of controls (P = 0.019). The 1-, 3-, and 5-year patient survival rates were 92.7%, 89.2%, and 86.9%, respectively, which were not different than those of controls (P = 0.11). LT recipients had lower recurrence and higher survival rates compared with HR patients (P < 0.001). The tumor recurrence site was mainly intrahepatic in HR patients. There was no difference between the incidences of extrahepatic recurrence in the HR study group and all-site recurrence in the LT study group (P = 0.61). We concluded that the prognostic effect of TACE-induced CPR for HCC patients appears to be limited to downstaging. LT recipients benefited more from CPR than HR patients. Liver Transplantation 23 781-790 2017 AASLD.
© 2017 by the American Association for the Study of Liver Diseases.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28240808     DOI: 10.1002/lt.24752

Source DB:  PubMed          Journal:  Liver Transpl        ISSN: 1527-6465            Impact factor:   5.799


  9 in total

1.  Bridging treatment prior to liver transplantation for hepatocellular carcinoma: radioembolization or transarterial chemoembolization?

Authors:  Tamás Benkö; Julia König; Jens M Theysohn; Clemens Schotten; Fuat H Saner; Jürgen Treckmann; Sonia Radunz
Journal:  Eur J Med Res       Date:  2022-05-26       Impact factor: 4.981

2.  Long-term results of laparoscopic liver resection for the primary treatment of hepatocellular carcinoma: role of the surgeon in anatomical resection.

Authors:  Woo-Hyoung Kang; Ki-Hun Kim; Dong-Hwan Jung; Gil-Chun Park; Seok-Hwan Kim; Hwui-Dong Cho; Sung-Gyu Lee
Journal:  Surg Endosc       Date:  2018-04-24       Impact factor: 4.584

3.  Long-term complete response after transcatheter arterial chemoembolization and stereotactic body radiation therapy in a patient with hepatocellular carcinoma at the caudate lobe.

Authors:  Yong-Kyu Chung; Shin Hwang; Gi-Young Ko; Sang Min Yoon
Journal:  Ann Hepatobiliary Pancreat Surg       Date:  2018-08-31

4.  PRIME-HCC: phase Ib study of neoadjuvant ipilimumab and nivolumab prior to liver resection for hepatocellular carcinoma.

Authors:  David J Pinato; Alessio Cortellini; Ajithkumar Sukumaran; Tom Cole; Madhava Pai; Nagy Habib; Duncan Spalding; Mikael H Sodergren; Maria Martinez; Tony Dhillon; Paul Tait; Robert Thomas; Caroline Ward; Hemant Kocher; Vincent Yip; Sarah Slater; Rohini Sharma
Journal:  BMC Cancer       Date:  2021-03-23       Impact factor: 4.430

5.  Hepatic arterial infusion chemotherapy versus transarterial chemoembolization for unresectable hepatocellular carcinoma: A systematic review with meta-analysis.

Authors:  Tengfei Si; Zhenlin Huang; Shirin Elizabeth Khorsandi; Yun Ma; Nigel Heaton
Journal:  Front Bioeng Biotechnol       Date:  2022-09-27

6.  Expression Patterns of Tumor Markers in Liver Transplant Recipients Showing Complete Pathological Response of Hepatocellular Carcinoma.

Authors:  Min-Jae Kim; Woo-Hyoung Kang; Shin Hwang; Chul-Soo Ahn; Deok-Bog Moon; Tae-Yong Ha; Gi-Won Song; Dong-Hwan Jung; Gil-Chun Park
Journal:  J Clin Med       Date:  2022-10-06       Impact factor: 4.964

7.  Microvascular invasion may be the determining factor in selecting TACE as the initial treatment in patients with hepatocellular carcinoma.

Authors:  Joonho Jeong; Jung Gu Park; Kwang Ill Seo; Ji Hyun Ahn; Jae Chun Park; Byung Cheol Yun; Sang Uk Lee; Jin Wook Lee; Jong Hyouk Yun
Journal:  Medicine (Baltimore)       Date:  2021-07-09       Impact factor: 1.889

8.  Validation of prognostic impact of ADV score for resection of hepatocellular carcinoma: analysis using Korea Liver Cancer Registry Database.

Authors:  Gil-Chun Park; Shin Hwang; Yo-Han Park; Jin-Uk Choi
Journal:  Ann Surg Treat Res       Date:  2020-04-28       Impact factor: 1.859

9.  Prognostic Relevance of a Complete Pathologic Response in Liver Transplantation for Hepatocellular Carcinoma.

Authors:  Michał Grąt; Marek Krawczyk; Jan Stypułkowski; Marcin Morawski; Maciej Krasnodębski; Michał Wasilewicz; Zbigniew Lewandowski; Karolina Grąt; Waldemar Patkowski; Krzysztof Zieniewicz
Journal:  Ann Surg Oncol       Date:  2019-09-13       Impact factor: 5.344

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.